EX-99.B 4 y54101ex99-b.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99(b) MERCK & CO., INC. THIRD QUARTER
3Q '01 3Q '00 % CHG. ---------- ---------- ---------- TOTAL SALES $ 11,919.6 $ 10,567.5 13% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 9,136.5 $ 7,925.9 ---------- ---------- Materials & Production 7,082.8 5,987.4 Marketing & Administrative 1,525.3 1,452.1 Research & Development 590.3 609.8 Equity Income From Affiliates (164.1) (219.4) Other (Income)/Expense, Net 102.2 96.0 PRE-TAX INCOME $ 2,783.1 $ 2,641.6 TAXES $ 834.9 $ 805.7 TAX RATE 30.0% 30.5% NET INCOME $ 1,948.2 $ 1,835.9 6% EPS - ASSUMING DILUTION $0.84 $0.78 8% AVG. # SHARES - ASSUMING DILUTION 2,312.4 2,342.9
3Q '01 % CHG. VOL PX FX ------- ------- ------- ------- ------- TOTAL SALES $11,920 13% 8 6 -1 ------- ------- ------- ------- ------- Total U.S. and Foreign Sales 5,470 6% 8 1 -3 ------- ------- ------- ------- ------- U.S 3,600 8% 6 2 0 Foreign 1,870 2% 11 -1 -8 Other Medco Sales 6,450 19%
Exhibit 99(b) MERCK & CO., INC. NINE MONTHS YEAR TO DATE
2001 2000 % CHG. ---------- ---------- ---------- TOTAL SALES $ 35,157.8 $ 28,895.9 22% ---------- ---------- TOTAL COSTS, EXPENSES, & OTHER $ 27,413.7 $ 21,582.9 ---------- ---------- Materials & Production 21,334.1 15,872.9 Marketing & Administrative 4,669.0 4,393.5 Research & Development 1,740.0 1,681.5 Equity Income From Affiliates (557.8) (619.5) Other (Income)/Expense, Net 228.4 254.5 PRE-TAX INCOME $ 7,744.1 $ 7,313.0 TAXES $ 2,323.2 $ 2,255.7 TAX RATE 30.0% 30.8% NET INCOME $ 5,420.9 $ 5,057.3 7% EPS - ASSUMING DILUTION $2.33 $2.15 8% AVG. # SHARES - ASSUMING DILUTION 2,329.1 2,351.6
2001 % CHG. VOL PX FX ------- ------- ------- ------- ------- TOTAL SALES $35,155 22% 17 6 -1 ------- ------- ------- ------- ------- Total U.S. and Foreign Sales 15,755 6% 8 1 -3 ------- ------- ------- ------- ------- U.S 10,105 7% 5 2 0 Foreign 5,650 5% 13 0 -8 Other Medco Sales 19,400 38%
Exhibit 99(b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2001 OTHER (INCOME)/EXPENSE, NET
3Q '01 3Q '00 YTD 2001 YTD 2000 -------- -------- -------- -------- INTEREST INCOME $ (114.6) $ (124.8) $ (380.3) $ (326.4) INTEREST EXPENSE 121.8 121.8 355.2 355.1 EXCHANGE (GAINS)/LOSSES 1.5 (14.3) (18.6) (31.8) MINORITY INTERESTS 72.3 74.8 218.3 230.8 AMORTIZATION OF GOODWILL AND INTANGIBLES 83.7 80.8 244.8 238.2 Other, net (62.5) (42.3) (191.0) (211.4) -------- -------- -------- -------- TOTAL $ 102.2 $ 96.0 $ 228.4 $ 254.5 ======== ======== ======== ========
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 3Q '01 3Q '00 YTD 2001 YTD 2000 ------ ------ ------ -------- -------- IVOMEC, HEARTGARD, other avermectins $ 130 $ 150 $ 365 $ 405 FRONTLINE 100 90 340 275 Biologicals 85 80 255 240 Other Animal Health 45 50 145 150 Poultry Genetics 50 55 155 165 ------ ------ ------ ------ TOTAL MERIAL SALES $ 410 $ 425 $1,260 $1,235 ====== ====== ====== ======
AVENTIS PASTEUR-MSD 3Q '01 3Q '00 YTD 2001 YTD 2000 ------------------- ------ ------ -------- -------- HEPATITIS VACCINES $ 20 $ 35 $ 70 $ 110 VIRAL VACCINES 10 10 35 35 Other Vaccines 125 125 265 260 ------ ------ ------ ------ TOTAL AP-MSD SALES $ 155 $ 170 $ 370 $ 405 ====== ====== ====== ======
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
2001 2000 % CHG ---- ---- ----- FIRST QUARTER 138 99 39% SECOND QUARTER 134 98 37% THIRD QUARTER 128 120 7% --- --- --- YEAR TO DATE 400 317 26% === === ===
Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
3Q '01 vs. 3Q '00 --------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- ------ ----- ------ ------- ------- VIOXX 29% $ 795 26% $ 625 42% $ 170 VASOTEC / VASERETIC -47% 245 -85% 30 -16% 215 PRINIVIL / PRINZIDE -10% 265 -8% 245 -33% 20 COZAAR / HYZAAR 33% 540 57% 275 15% 265 MEVACOR -19% 110 -18% 90 -20% 20 ZOCOR 28% 1,740 40% 1,270 3% 470 AGGRASTAT -29% 25 -40% 15 0% 10 SINGULAIR 49% 350 42% 270 78% 80 MAXALT 56% 70 71% 60 0% 10 PROPECIA 10% 55 0% 25 20% 30 PROSCAR 17% 140 8% 70 27% 70 PRIMAXIN 0% 140 0% 40 0% 100 CANCIDAS N/M 10 N/M 10 N/M -- PEPCID -82% 35 -89% 20 0% 15 FOSAMAX 25% 450 23% 320 30% 130 CRIXIVAN/STOCRIN -18% 115 30% 65 -44% 50 TIMOPTIC/TIMOPTIC XE -17% 50 0% 15 -22% 35 TRUSOPT/COSOPT 11% 100 0% 45 22% 55 HEPATITIS VACCINES -5% 100 -5% 90 0% 10 VIRAL VACCINES 3% 160 3% 150 0% 10 OTHER VACCINES N/M 50 N/M 25 N/M 25
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful Exhibit 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
9 MONTHS YTD 2001 OVER 2000 --------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- ------ ----- ------ ------- ------- VIOXX 37% $2,005 30% $1,530 67% $ 475 VASOTEC / VASERETIC -45% 800 -83% 110 -16% 690 PRINIVIL / PRINZIDE 13% 940 16% 870 -18% 70 COZAAR / HYZAAR 21% 1,435 27% 640 17% 795 MEVACOR -1% 390 3% 330 -20% 60 ZOCOR 21% 4,615 31% 3,190 3% 1,425 AGGRASTAT -15% 85 -27% 55 20% 30 SINGULAIR 67% 1,025 67% 800 67% 225 MAXALT 52% 205 57% 165 33% 40 PROPECIA 7% 160 21% 85 -6% 75 PROSCAR 19% 410 27% 210 11% 200 PRIMAXIN -2% 440 0% 130 -3% 310 CANCIDAS N/M 25 N/M 20 N/M 5 PEPCID -46% 330 -50% 280 -9% 50 FOSAMAX 34% 1,290 40% 940 21% 350 CRIXIVAN/STOCRIN -18% 335 -3% 150 -27% 185 TIMOPTIC/TIMOPTIC XE -13% 165 -10% 45 -14% 120 TRUSOPT/COSOPT 13% 300 16% 145 11% 155 HEPATITIS VACCINES 0% 270 0% 245 0% 25 VIRAL VACCINES 5% 425 4% 395 20% 30 OTHER VACCINES N/M 100 N/M 65 N/M 35
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful